Curis’ (CRIS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Curis (NASDAQ:CRIS) in a report published on Friday,Benzinga reports. The brokerage currently has a $20.00 price target on the biotechnology company’s stock.

Curis Trading Down 0.8 %

NASDAQ CRIS opened at $3.95 on Friday. Curis has a 1 year low of $3.51 and a 1 year high of $17.49. The company has a market cap of $23.62 million, a PE ratio of -0.51 and a beta of 3.35. The stock’s 50-day moving average price is $5.01 and its two-hundred day moving average price is $7.06.

Institutional Investors Weigh In On Curis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRIS. Vanguard Group Inc. increased its stake in shares of Curis by 4.8% in the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after acquiring an additional 10,097 shares during the last quarter. Focused Wealth Management Inc increased its position in Curis by 63.1% in the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 20,908 shares during the last quarter. CM Management LLC raised its stake in shares of Curis by 380.0% during the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after purchasing an additional 95,000 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Curis by 795.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after buying an additional 96,256 shares during the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.